Amgen

For nearly a year, Andy and his wife Kat searched for answers on his journey to an eventual IgG4-related disease (IgG4-RD) diagnosis. At first, scans revealed masses in his lungs, and doctors feared it might be cancer. But after months of tests and specialist visits, Andy was finally diagnosed with IgG4-RD — a rare inflammatory condition often called “the great mimicker” because it can resemble many other diseases. This #IgG4RDAwareness Day, Amgen is proud to work alongside AiArthritis (International Foundation for Autoimmune & Autoinflammatory Arthritis), the American Kidney Fund, the Global Healthy Living Foundation, the IgG4ward! Foundation, Mission: Cure and the Vasculitis Foundation to help patients and healthcare providers recognize IgG4-RD sooner and improve pathways to care. Today, Andy and Kat are thriving in their efforts to raise awareness for this disease and raise their three boys. 🔗 Learn more about Andy and Kat’s journey: https://amgen.ly/4sfLlku #IgG4RD #RareDisease

Amgen has published its 2025 Letter to Shareholders. 🔗 https://amgen.ly/4bJMCeF This year’s letter highlights our strong performance in 2025 and how we are advancing innovative medicines, driving scientific innovation, and investing in manufacturing to better serve patients around the world.

Bilimle fark yaratmaya hazır mısın? Amgen Türkiye’nin genç bilim insanlarını destekleyen IamGenius Biyoteknolojik Fikirler Yarışması başladı. Adım adım başvuru sürecini keşfet ve sen de bu yolculuğun bir parçası ol! #AmgenTürkiye #IamGenius #Biotech #AI #Internship

The evidence is clear: lowering LDL (“bad”) cholesterol earlier in the care continuum reduces cardiovascular risk. Amgen presented data at the American College of Cardiology’s Scientific Sessions #ACC26 focused on high-risk patients with no known atherosclerosis. The findings reinforce the importance of reducing LDL-C earlier in high-risk patients before ASCVD takes hold. ➡️ Read the Press Release: https://amgen.ly/4dbKyx5

At Amgen, AI is helping improve how decisions are made to support how medicines are discovered, developed and delivered. In this sponsored article for WIRED, Amgen leaders David Reese and Sean Bruich share how that work is showing up in practice. AI tools are on track to help Amgen reduce the duration of certain changeovers by as much as 36 percent. It’s a practical view of how biology, data and technology come together to navigate complexity, move faster, and keep patients at the center. See what applied AI looks like at Amgen: https://amgen.ly/4bUaRWp

Amgen has been named one of the 2026 World’s Most Ethical Companies® by Ethisphere, a recognition that reflects how we do our work, not just what we achieve. From advancing science to serving patients, "Be Ethical” is a core component of the Amgen Values. This honor belongs to our teams around the world who hold themselves to the highest standards every day. Read more here: amgen.ly/7936 about this exciting news. “World’s Most Ethical Companies” and “Ethisphere” names and marks are registered trademarks of Ethisphere LLC.

When your work touches the lives of patients around the world, supporting the people behind it matters more than ever. Managers like Aine play a critical role in safeguarding their teams’ safety and wellbeing—enabling the seamless production, packaging, and distribution of life‑changing biologics that reach patients worldwide. Learn more about how we put our people first and our mission to serve patients worldwide: https://amgen.ly/4szqnxX #LifeAtAmgen #AmgenCareers

At Amgen, uncovering new markers to treat diseases is personal. For Justin Murray, Senior Director of Research at Amgen, that came into focus when a colleague's cardiac event revealed elevated lipoprotein(a), a genetic risk factor for cardiovascular disease, often not included in routine lipid panels. That’s why we’re working toward a future where complete cardiovascular risk assessment isn't the exception, it's the standard. This #LpaAwarenessDay, learn what our scientists are uncovering about Lp(a) and why it matters: https://amgen.ly/4d6H7rx

В края на седмицата ще се проведе IV Научна конференция „Основи на сърдечно-съдовата фармакотерапия. Новите терапии при сърдечно-съдовите заболявания“ – форум, посветен на най-актуалните постижения и иновации в лечението и профилактиката на сърдечно-съдовите и кардиометаболитните заболявания. Събитието, спонсорирано от Amgen, се организира по инициатива на Фондация „Академия-Кардиология”, Фондация „Логартис” и „Арбилис” ООД, съвместно с Националното сдружение на общопрактикуващите лекари в България и Българското научно дружество по фармация. 🔎 Фокус в програмата се поставя на ключови научни направления в съвременната сърдечно-съдова терапия, иновациите в липидопонижаващата терапия, и оптималните стратегии за контрол на LDL-холестерола с цел редукция на сърдечно-съдовия риск. Ако работите в областта на кардиологията, общата медицина, клиничната фармация или кардиометаболитните заболявания – това е място за реална научна стойност, практическа насоченост и обмен на опит. #Amgen

The conversations that shape our health often begin long before a doctor’s visit. Amgen’s panel at SXSW — where innovation, culture, and community intersect — brought cardiovascular health to a broader stage, encouraging dialogue that can inspire earlier action. Swipe to see how voices across advocacy, sports and media are helping redefine the narrative around cardiovascular risk. From our discussion with Barry Sanders on the influence athletes can have on health decisions to broader conversations around LDL (“bad”) cholesterol and cardiovascular risk, we’re helping bring trusted voices to the forefront. Learn more here: https://amgen.ly/3NXV68G #SXSW2026